Losartan Effects on Emphysema Progression (LEEP)
The American Lung Association Airways Clinical Research Center (ACRC) network is teaming up with the Pulmonary Trials Cooperative (PTC) to study a potential treatment for COPD. Chronic Obstructive Pulmonary Disease (COPD) is a lung disease that makes it hard to breathe. There is no cure for COPD. More than 15 million people in the United States have COPD. Although there are ways to reduce symptoms, there is no treatment that has been shown to slow COPD progression. The ACRC will use images of patients’ lungs taken with a High Resolution Computed Tomography (HRCT) scan. These scans are a way to measure the amount of emphysema in a patient. Patients will have emphysema measured on 2 HRCT scans; one will be performed at the start of the study and the other after at the end, about 11 months later. LEEP will study whether a medicine called Losartan can slow lung damage in people who have COPD with emphysema. Currently, Losartan is approved by the Food and Drug Administration (FDA) for the treatment of high blood pressure. The LEEP trial is a 1 year study. There are 7 clinic visits. Participants will be randomly assigned to take Losartan or placebo (a capsule with no active drug in it) daily for a year. Randomization is like flipping a coin, patients have an equal chance to get losartan or placebo. The ACRC is looking for current or former smokers over 40 years old with COPD and emphysema to participate in the LEEP trial.
April 1, 2017 - July 1, 2019